Abstract Background Drug-drug interactions (DDIs) in subjects enrolling in clinical trials can impact not only safety of the patient but also study drug outcomes and data validity. This makes it critical to adequately screen and manage DDIs. The study objective was to determine the prevalence of DDIs involving study medications in subjects enrolling in National Clinical Trials Network (NCTN) clinical trials at a single institution. DDIs were evaluated based on study protocol recommendations for concomitant medication use (i.e. exclude, avoid or use caution), screening via DDI tool, and pharmacist review. Methods Subjects enrolled in ...
Background and objective Drug interactions are an under-recognized and not much studied issue in onc...
Background: In this study, it is aimed to explain the type and frequency of potential drug-drug inte...
Drug-drug interactions (DDIs) with anticancer drugs are common and can significantly affect efficacy...
Abstract Background Drug-drug interactions (DDIs) in subjects enrolling in clinical trials can impac...
Abstract Background Patients with cancer are at incre...
Background: Drug-drug interactions (DDIs) are of major concern in oncology, since cancer patients ty...
Methods: We searched PubMed for eligible articles and on-line databases for abstracts of major oncol...
Background: Drug-drug interactions (DDIs) are of major concern in oncology, since cancer patients ty...
International audienceBACKGROUND: Drug-drug interactions (DDIs) may occur with investigational drugs...
BackgroundDrug–drug interactions (DDIs) can negatively affect pharmacotherapy. However, pediatric DD...
Background: When a patient concomitantly uses two or more drugs, a drug-drug interaction (DDI) can p...
Background: Potential drug-drug interactions (PDDIs) in patients with cancer are common, but have no...
Background: Drug-drug interactions (DDIs) comprise an important problem in medical oncology practice...
Abstract Introduction: A Drug-drug interaction (DDI) is a decrease or increase in the pharmac...
Background: Critically ill-patients frequently receive multidrug regimens (polypharmacy) with the go...
Background and objective Drug interactions are an under-recognized and not much studied issue in onc...
Background: In this study, it is aimed to explain the type and frequency of potential drug-drug inte...
Drug-drug interactions (DDIs) with anticancer drugs are common and can significantly affect efficacy...
Abstract Background Drug-drug interactions (DDIs) in subjects enrolling in clinical trials can impac...
Abstract Background Patients with cancer are at incre...
Background: Drug-drug interactions (DDIs) are of major concern in oncology, since cancer patients ty...
Methods: We searched PubMed for eligible articles and on-line databases for abstracts of major oncol...
Background: Drug-drug interactions (DDIs) are of major concern in oncology, since cancer patients ty...
International audienceBACKGROUND: Drug-drug interactions (DDIs) may occur with investigational drugs...
BackgroundDrug–drug interactions (DDIs) can negatively affect pharmacotherapy. However, pediatric DD...
Background: When a patient concomitantly uses two or more drugs, a drug-drug interaction (DDI) can p...
Background: Potential drug-drug interactions (PDDIs) in patients with cancer are common, but have no...
Background: Drug-drug interactions (DDIs) comprise an important problem in medical oncology practice...
Abstract Introduction: A Drug-drug interaction (DDI) is a decrease or increase in the pharmac...
Background: Critically ill-patients frequently receive multidrug regimens (polypharmacy) with the go...
Background and objective Drug interactions are an under-recognized and not much studied issue in onc...
Background: In this study, it is aimed to explain the type and frequency of potential drug-drug inte...
Drug-drug interactions (DDIs) with anticancer drugs are common and can significantly affect efficacy...